Study identification

EU PAS number

EUPAS12771

Study ID

12772

Official title and acronym

An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Prospective Study Evaluating Retention Rate, Seizure Control and Tolerability of Eslicarbazepine Acetate (ESL) as Adjunctive Treatment to One Baseline Antiepileptic Drug in Adult Patients With Partial-Onset Seizures With or Without Secondary Generalisation (EPOS)

DARWIN EU® study

No

Study countries

Czechia
Denmark
France
Germany
Ireland
Norway
Sweden
United Kingdom

Study description

This was a Non-interventional Prospective Study. Centres enrolled adult patients with partial-onset seizures with or without secondary generalisation for whom the clinician had decided to initiate Eslicarbazepine Acetate (ESL) as an adjunctive therapy prior to the decision to take part in this study. Patients enrolled into the study were not sufficiently controlled with one drug licensed for the use as monotherapy in partial-onset seizures. Patients were seen at baseline and then during normal clinical visits at intervals. Patients in this study were assessed for efficacy and tolerability at baseline and then at least 3 and 6 months after the baseline.

Study status

Finalised
Research institutions and networks

Institutions

Klinische und Experimentelle Epileptologie,Klinik für Neurologie
Multiple centres: 107 centres are involved in the study

Contact details

Martin Holtkamp

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eisai Limited
Regulatory

Was the study required by a regulatory body?

No